{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:59:42Z","timestamp":1790495982840,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1124\/jpet.109.154443","type":"journal-article","created":{"date-parts":[[2009,6,25]],"date-time":"2009-06-25T21:52:06Z","timestamp":1245966726000},"page":"964-970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease"],"prefix":"10.1016","volume":"330","author":[{"given":"Robert N.","family":"Willette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne E.","family":"Eybye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Olzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Behm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nambi","family":"Aiyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristeen","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross G.","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Coatney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Westfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris P.","family":"Doe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.109.154443_bib1","doi-asserted-by":"crossref","unstructured":"Aw TJ, Haas SJ, Liew D, and Krum H (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165: 490-496.","DOI":"10.1001\/archinte.165.5.ioi50013"},{"key":"10.1124\/jpet.109.154443_bib2","doi-asserted-by":"crossref","unstructured":"Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, Johns DG, Woods TN, Doe CP, Coatney RW, et al. (2007) Effects of p38 MAPK inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 49: 362-368.","DOI":"10.1097\/FJC.0b013e318046f34a"},{"key":"10.1124\/jpet.109.154443_bib3","doi-asserted-by":"crossref","unstructured":"Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, and Douglas SA (2002) Pharmacological characterization of SB-710411 (Cpa-c[d-Cys-Pal-d-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 137: 449-458.","DOI":"10.1038\/sj.bjp.0704887"},{"key":"10.1124\/jpet.109.154443_bib4","unstructured":"Behr TM, Berova M, Doe CP, Ju H, Angermann CE, Boehm J, and Willette RN (2003) p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Curr Opin Investig Drugs 4: 1059-1064."},{"key":"10.1124\/jpet.109.154443_bib5","doi-asserted-by":"crossref","unstructured":"Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, et al. (2001) Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104: 1292-1298.","DOI":"10.1161\/hc3601.094275"},{"key":"10.1124\/jpet.109.154443_bib6","doi-asserted-by":"crossref","unstructured":"Berg AH and Scherer PE (2005) Adipose tissue, inflammation, and cardiovascular disease [Review]. Circ Res 96: 939-949.","DOI":"10.1161\/01.RES.0000163635.62927.34"},{"key":"10.1124\/jpet.109.154443_bib7","doi-asserted-by":"crossref","unstructured":"Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier, et al. (1999) Rofecoxib [vioxx, MK-0966; 4-(4\u2032-methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290: 551-560.","DOI":"10.1016\/S0022-3565(24)34934-1"},{"key":"10.1124\/jpet.109.154443_bib8","doi-asserted-by":"crossref","unstructured":"Chenevard R, H\u00fcrlimann D, B\u00e9chir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, et al. (2003) Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107: 405-409.","DOI":"10.1161\/01.CIR.0000051361.69808.3A"},{"key":"10.1124\/jpet.109.154443_bib9","doi-asserted-by":"crossref","unstructured":"De Tena JG, Kriszbacher I, Kopp\u00e1n M, B\u00f3dis J, and Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease [5] (multiple letters). N Engl J Med 353: 429-430.","DOI":"10.1056\/NEJM200507283530425"},{"key":"10.1124\/jpet.109.154443_bib10","doi-asserted-by":"crossref","unstructured":"Forrester JS and Libby P (2007) The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 99: 732-738.","DOI":"10.1016\/j.amjcard.2006.09.125"},{"key":"10.1124\/jpet.109.154443_bib11","doi-asserted-by":"crossref","unstructured":"Grundy SM (2003) Inflammation hypertension, and the metabolic syndrome. JAMA 290: 3000-3002.","DOI":"10.1001\/jama.290.22.3000"},{"key":"10.1124\/jpet.109.154443_bib12","doi-asserted-by":"crossref","unstructured":"Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, and Willette RN (2003) p38 MAPK inhibitors ameliorate target organ damage in hypertension. Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther 307: 932-938.","DOI":"10.1124\/jpet.103.057422"},{"key":"10.1124\/jpet.109.154443_bib13","doi-asserted-by":"crossref","unstructured":"Ju H, Nerurkar S, Sauermelch CF, Olzinski AR, Mirabile R, Zimmerman D, Lee JC, Adams J, Sisko J, Berova M, et al. (2002) Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury. J Pharmacol Exp Ther 301: 15-20.","DOI":"10.1124\/jpet.301.1.15"},{"key":"10.1124\/jpet.109.154443_bib14","doi-asserted-by":"crossref","unstructured":"Li H, Hortmann M, Daiber A, Oelze M, Ostad MA, Schwarz PM, Xu H, Xia N, Kleschyov AL, Mang C, et al. (2008) Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther 326: 745-753.","DOI":"10.1124\/jpet.108.139030"},{"key":"10.1124\/jpet.109.154443_bib15","doi-asserted-by":"crossref","unstructured":"Li Z, Tran TT, Ma JY, O\u2019Young G, Kapoun AM, Chakravarty S, Dugar S, Schreiner G, and Protter AA (2004) p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats. J Cardiovasc Pharmacol 44: 486-492.","DOI":"10.1097\/01.fjc.0000141474.06383.6f"},{"key":"10.1124\/jpet.109.154443_bib16","doi-asserted-by":"crossref","unstructured":"Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 109: 1594-1602.","DOI":"10.1161\/01.CIR.0000124490.27666.B2"},{"key":"10.1124\/jpet.109.154443_bib17","doi-asserted-by":"crossref","unstructured":"Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R, Willette RN, and Jucker BM (2008) p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler Thromb Vasc Biol 28: 265-271.","DOI":"10.1161\/ATVBAHA.107.151175"},{"key":"10.1124\/jpet.109.154443_bib18","doi-asserted-by":"crossref","unstructured":"Olzinski AR, McCafferty TA, Zhao SQ, Behm DJ, Eybye ME, Maniscalco K, Bentley R, Frazier KS, Milliner CM, Mirabile RC, et al. (2005) Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: Role of systemic blood pressure and endothelial protection. Cardiovasc Res 66: 170-178.","DOI":"10.1016\/j.cardiores.2004.12.021"},{"key":"10.1124\/jpet.109.154443_bib19","doi-asserted-by":"crossref","unstructured":"Park JK, Fischer R, Dechend R, Shagdarsuren E, Gapeljuk A, Wellner M, Meiners S, Gratze P, Al-Saadi N, Feldt S, et al. (2007) p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension 49: 481-489.","DOI":"10.1161\/01.HYP.0000256831.33459.ea"},{"key":"10.1124\/jpet.109.154443_bib20","doi-asserted-by":"crossref","unstructured":"Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Cr\u00e9minon C, and Maclouf J (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271: 1705-1712.","DOI":"10.1016\/S0022-3565(25)24061-7"},{"key":"10.1124\/jpet.109.154443_bib21","doi-asserted-by":"crossref","unstructured":"Savoia C and Schiffrin EL (2007) Vascular inflammation in hypertension and diabetes: Molecular mechanisms and therapeutic interventions. Clin Sci 112: 375-384.","DOI":"10.1042\/CS20060247"},{"key":"10.1124\/jpet.109.154443_bib22","doi-asserted-by":"crossref","unstructured":"Schieffer B, B\u00fcnte C, Witte J, Hoeper K, B\u00f6ger RH, Schwedhelm E, and Drexler H (2004) Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44: 362-368.","DOI":"10.1016\/j.jacc.2004.03.065"},{"key":"10.1124\/jpet.109.154443_bib23","doi-asserted-by":"crossref","unstructured":"Schieven GL (2005) The biology of p38 kinase: a central role in inflammation. Curr Top Med Chemistry 5: 921-928.","DOI":"10.2174\/1568026054985902"},{"key":"10.1124\/jpet.109.154443_bib24","doi-asserted-by":"crossref","unstructured":"Touyz RM (2003) Recent advances in intracellular signalling in hypertension. Curr Opin Nephrol Hypertens 12: 165-174.","DOI":"10.1097\/00041552-200303000-00007"},{"key":"10.1124\/jpet.109.154443_bib25","doi-asserted-by":"crossref","unstructured":"Widder J, Behr T, Fraccarollo D, Hu K, Galuppo P, Tas P, Angermann CE, Ertl G, and Bauersachs J (2004) Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. Cardiovasc Res 63: 161-167.","DOI":"10.1016\/j.cardiores.2004.03.008"},{"key":"10.1124\/jpet.109.154443_bib26","doi-asserted-by":"crossref","unstructured":"Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF Jr, Morrow JD, et al. (2003) Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42: 310-315.","DOI":"10.1161\/01.HYP.0000084603.93510.28"},{"key":"10.1124\/jpet.109.154443_bib27","doi-asserted-by":"crossref","unstructured":"Willerson JT and Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109: II-2-II-10.","DOI":"10.1161\/01.CIR.0000129535.04194.38"},{"key":"10.1124\/jpet.109.154443_bib28","doi-asserted-by":"crossref","unstructured":"Wong M, Jiang BY, McNeill K, Farish S, Kirkham B, and Chowienczyk P (2007) Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol 36: 265-269.","DOI":"10.1080\/03009740701286771"},{"key":"10.1124\/jpet.109.154443_bib29","doi-asserted-by":"crossref","unstructured":"Zarraga IG and Schwarz ER (2007) Coxibs and heart disease. what we have learned and what else we need to know. J Am Coll Cardiol 49: 1-14.","DOI":"10.1016\/j.jacc.2006.10.003"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524385738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524385738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.109.154443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:34:57Z","timestamp":1739997297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524385738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0022356524385738"],"URL":"https:\/\/doi.org\/10.1124\/jpet.109.154443","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.109.154443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}